Profil
Actuellement, Klaus Henning Jensen est Chief Medical Officer de Vifor Pharma AG. Par le passé, le Dr Jensen a occupé le poste de responsable du domaine thérapeutique et du développement du diabète chez Sanofi. Le Dr Jensen a obtenu un doctorat de l'université de Copenhague et un MBA de la Copenhagen Business School.
Anciens postes connus de Klaus Jensen
| Sociétés | Poste | Fin |
|---|---|---|
| SANOFI | Corporate Officer/Principal | 01/12/2019 |
| NOVO NORDISK A/S | General Counsel | - |
| VIFOR PHARMA | Chief Tech/Sci/R&D Officer | - |
Formation de Klaus Jensen
| Copenhagen Business School | Masters Business Admin |
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| SANOFI | Health Technology |
| Entreprise privées | 1 |
|---|---|
Vifor Pharma AG
 Vifor Pharma AG Pharmaceuticals: MajorHealth Technology Vifor Pharma AG is a pharmaceutical company, which engages in the research, development, production, and marketing of therapeutic products. It operates through the following geographical segments: Switzerland, Europe, USA, Rest of World, and Group. The firm offers products for iron deficiency, nephrology, and cardio-renal therapies. It specializes in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision patient care. The company was founded in 1927 and is headquartered in St. Gallen, Switzerland. | Health Technology |
